Company Info

Failed to load

Spyre Therapeutics, Inc.

Technology

Overview

Failed to load

Contributions

Contributors

Contributions

1 Contributions1 / 1

Failed to load

Antibody

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics, Inc.

PR-12-24-NI-125Dec 03, 2024

1 / 1

0 Contributors1 / 0

No authors found

1 / 0